FDA Calls for Boycott of Cantrell Drugs

A March 1^st FDA Press Announcement noted that the agency has asked physicians and patients to cease the use of drug products produced at Cantrell Drug Company’s Little Rock facility. This includes a variety of drugs including opioids that are linked to deficiencies in Cantrell’s quality and sterility assurance processes. FDA Commissioner Scott Gottlieb referred to the facility’s conditions as “egregious” and their continued distribution of drugs without addressing potential danger as a “reckless activity.”